UWorld Pharmacy Book
Updates and Errata
Home » Guideline/Drug Updates and Errata
RxPrep content (e.g., NAPLEX Course Book, MPJE/CPJE Manuals and QBanks) is up-to-date at the time of publishing, but drug information and laws can change at any time. If information changes after a product is published, we will post exam-relevant updates in the Guideline/Drug Updates tables below. If we find anything that needs a correction or clarification, it will be included in the Errata tables below.
Updates: 2025 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2024 – May 2025
Page | Update Type | Description | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chapter 1: Preparing for the NAPLEX with UWorld RxPrep | ||||||||||||||||
P. 8 | New NAPLEX Content Outline Effective May 1, 2025 |
NABP released a new NAPLEX Content Outline (their blueprint of tested items), which will go into effect on May 1, 2025. Impact for NAPLEX Candidates testing after May 1, 2025:
New NAPLEX Content Domains for 2025:
The basic competencies required to practice as a pharmacist have not changed. Extensive knowledge about medications and their safe use (ie, Domains 1, 2, and 3) is still required. This will represent 90% of the questions on the NAPLEX. Content from Domains 4 and 5 (representing 10% of the scored questions) is included in UWorld RxPrep material in the following chapters and QBanks:
|
||||||||||||||
Chapter 20: Immunizations | ||||||||||||||||
P. 290, 291 & 296 | Pneumococcal Vaccine Updates |
There are two updates related to pneumococcal vaccination:
|
||||||||||||||
P. 294 & 297 | Seasonal Vaccine Update |
Relevant updates from the Centers for Disease Control & Prevention (CDC) for the 2024–2025 respiratory virus season include:
|
||||||||||||||
Chapter 26: Human Immunodeficiency Virus | ||||||||||||||||
P. 382 | Guideline Update |
The single tablet regimen containing dolutegravir/abacavir/lamivudine (Triumeq) is no longer recommended as a preferred initial antiretroviral therapy regimen for treatment-naive patients with HIV. It is an alternative regimen that can be considered for certain clinical scenarios (eg, unable to tolerate a first-line regimen) if pretreatment testing for HLA-B*5701 is negative. |
||||||||||||||
Chapter 44: Diabetes | ||||||||||||||||
P. 580 | Guideline Update |
The 2025 American Diabetes Association (ADA) Standards of Care update was published. The most relevant update for testing is that the guidelines now recommend either an SGLT2 inhibitor or a GLP-1 receptor agonist with demonstrated benefit for use in patients with type 2 diabetes and CKD. Treatment algorithm, CKD arm:In the “First Drug” section, under the GLP-1a, cross out “(if SGLT2i not tolerated or contraindicated)”. |
||||||||||||||
P. 581 | New Indication |
The FDA has approved semaglutide (Ozempic) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. |
Updates: 2026 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2025 – May 2026
Page | Update Type | Description |
---|---|---|
Chapter 23: Infectious Diseases II: Bacterial Infections | ||
P. 397 | Guideline Update |
The American Academy of Otolaryngology–Head and Neck Surgery Foundation published an updated guideline on managing acute sinusitis. Relevant updates for testing include:
|
Chapter 26: Human Immunodeficiency Virus | ||
P. 451 | New indication | Lenacapavir (Yeztugo) has been approved for HIV pre-exposure prophylaxis (PrEP). It is a subcutaneous injection administered every 6 months. Testing for HIV (to confirm a negative result) is required at baseline and every 6 months thereafter. |
Chapter 28: Hypertension | ||
P. 474 | Guideline Update |
The 2025 AHA/ACC Guidelines for Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults were published. Relevant updates for testing include: Initiation of pharmacotherapy is recommended for adults with stage 1 hypertension who have one of the following:
Initiation of dual therapy (ie, 2 first-line agents in different classes), preferably as a single-pill combination, is recommended for all adults with stage 2 hypertension who have SBP ≥ 140 mmHg and DBP ≥ 90 mmHg. |
Chapter 63: Schizophrenia/Psychosis | ||
P. 944 | Package Labeling Update |
Following the removal of the REMS program, several updates were made to the package labeling for clozapine regarding the recommended monitoring parameters for the risk of agranulocytosis.
|
Updates: 2026 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2025 – May 2026
Chapter 23: Infectious Diseases II: Bacterial Infections | ||
Page P. 397 |
Update Type Guideline Update |
|
The American Academy of Otolaryngology–Head and Neck Surgery Foundation published an updated guideline on managing acute sinusitis. Relevant updates for testing include:
|
||
Chapter 26: Human Immunodeficiency Virus | ||
Page P. 451 |
Update Type New indication |
|
Lenacapavir (Yeztugo) has been approved for HIV pre-exposure prophylaxis (PrEP). It is a subcutaneous injection administered every 6 months. Testing for HIV (to confirm a negative result) is required at baseline and every 6 months thereafter. |
||
Chapter 28: Hypertension | ||
Page P. 474 |
Update Type Guideline Update |
|
The 2025 AHA/ACC Guidelines for Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults were published. Relevant updates for testing include: Initiation of pharmacotherapy is recommended for adults with stage 1 hypertension who have one of the following:
Initiation of dual therapy (ie, 2 first-line agents in different classes), preferably as a single-pill combination, is recommended for all adults with stage 2 hypertension who have SBP ≥ 140 mmHg and DBP ≥ 90 mmHg. |
||
Chapter 63: Schizophrenia/Psychosis | ||
Page P. 944 |
Update Type Package Labeling Update |
|
Following the removal of the REMS program, several updates were made to the package labeling for clozapine regarding the recommended monitoring parameters for the risk of agranulocytosis.
|
Updates: 2025 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2024 – May 2025
Chapter 1: Preparing for the NAPLEX with UWorld RxPrep | ||||||||||||||||
Page P. 8 |
Update Type New NAPLEX Content Outline Effective May 1, 2025 |
|||||||||||||||
NABP released a new NAPLEX Content Outline (their blueprint of tested items), which will go into effect on May 1, 2025. Impact for NAPLEX Candidates testing after May 1, 2025:
New NAPLEX Content Domains for 2025:
The basic competencies required to practice as a pharmacist have not changed. Extensive knowledge about medications and their safe use (ie, Domains 1, 2, and 3) is still required. This will represent 90% of the questions on the NAPLEX. Content from Domains 4 and 5 (representing 10% of the scored questions) is included in UWorld RxPrep material in the following chapters and QBanks:
|
||||||||||||||||
Chapter 20: Immunizations | ||||||||||||||||
Page P. 290, 291 & 296 |
Update Type Pneumococcal Vaccine Updates |
|||||||||||||||
There are two updates related to pneumococcal vaccination:
|
||||||||||||||||
Page P. 294 & 297 |
Update Type Seasonal Vaccine Update |
|||||||||||||||
Relevant updates from the Centers for Disease Control & Prevention (CDC) for the 2024–2025 respiratory virus season include:
|
||||||||||||||||
Chapter 26: Human Immunodeficiency Virus | ||||||||||||||||
Page P. 382 |
Update Type Guideline Update |
|||||||||||||||
The single tablet regimen containing dolutegravir/abacavir/lamivudine (Triumeq) is no longer recommended as a preferred initial antiretroviral therapy regimen for treatment-naive patients with HIV. It is an alternative regimen that can be considered for certain clinical scenarios (eg, unable to tolerate a first-line regimen) if pretreatment testing for HLA-B*5701 is negative. |
||||||||||||||||
Chapter 44: Diabetes | ||||||||||||||||
Page P. 580 |
Update Type Guideline Update |
|||||||||||||||
The 2025 American Diabetes Association (ADA) Standards of Care update was published. The most relevant update for testing is that the guidelines now recommend either an SGLT2 inhibitor or a GLP-1 receptor agonist with demonstrated benefit for use in patients with type 2 diabetes and CKD.
Treatment algorithm, CKD arm: |
||||||||||||||||
Page P. 581 |
Update Type New Indication |
|||||||||||||||
The FDA has approved semaglutide (Ozempic) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. |
MPJE Updates: 8th Edition MPJE Review Course
MPJE-relevant updates from April 2024 – present
Page | Update Type | Description | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Chapter 8: Controlled Substances Part 3: Prescribing and Dispensing | ||||||||||
p. 152 | Law change Effective October 2024 |
Restrictions for a take-home supply of methadone for opioid use disorder (OUD) have been simplified and are now permissive of larger quantities. Opioid Treatment Programs are allowed to dispense up to a 28-day supply of methadone for unsupervised self-administration (ie, “take-home”) to qualifying patients for treatment of OUD. Medical practitioners are responsible for determining which patients qualify for a take-home supply based on criteria listed in the regulation (eg, absence of known recent diversion activity, regularity of attendance for supervised methadone administration) in addition to other factors that indicate that the benefits of unsupervised doses outweigh the risks.
|
MPJE Updates: 8th Edition MPJE Review Course
MPJE-relevant updates from April 2024 – present
Chapter 8: Controlled Substances Part 3: Prescribing and Dispensing | ||||||||||
Page p. 152 |
Update Type Law change Effective October 2024 |
|||||||||
Restrictions for a take-home supply of methadone for opioid use disorder (OUD) have been simplified and are now permissive of larger quantities. Opioid Treatment Programs are allowed to dispense up to a 28-day supply of methadone for unsupervised self-administration (ie, “take-home”) to qualifying patients for treatment of OUD. Medical practitioners are responsible for determining which patients qualify for a take-home supply based on criteria listed in the regulation (eg, absence of known recent diversion activity, regularity of attendance for supervised methadone administration) in addition to other factors that indicate that the benefits of unsupervised doses outweigh the risks.
|
CPJE Updates: 8th Edition California Law Summary for CPJE
CPJE-relevant updates from June 2023 – present
Page | Update Type | Description | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Chapter 2: Pharmacy Operations | ||||||||||
p. 7 |
Law update Effective April 1, 2025 |
A new update to the California Code of Regulations (CCR) includes additional requirements for designating a pharmacist-in-charge (PIC):
|
||||||||
p. 8 |
Law update Effective July 2024 |
Continuing education (CE) requirements for pharmacist licensure renewal have been updated. Pharmacists who prescribe schedule II controlled substances must complete at least 1 hour of CE every 4 years pertaining to the risk of addiction associated with these medications. |
||||||||
p. 19 |
Law change Effective January 2023 |
Controlled substance inventory reports must be prepared using an exact physical count, not an estimate, for all federal controlled substance schedules (i.e., schedules II–V) that a pharmacy has in stock (both unopened and opened containers). Prior to this law change, an estimated count was permissible for opened containers of schedule III–V controlled substances based on the number of dosage units. |
||||||||
Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||||||||||
p. 49-50 | Law update |
The Notice to Consumers poster has been updated. The poster is now titled “Talk to the Expert” and must replace the “Ask Your Pharmacist!” poster. The content of the poster has been updated to caution consumers to “check” for a list of key information regarding their prescription before leaving the pharmacy. The poster continues to notify consumers of their rights as a patient at the pharmacy. The new poster also includes a QR code that links consumers to other language translations of the poster. If the poster is displayed using a video screen, the QR code must still be capable of being read and displayed for sufficient time for consumers to access the code. |
||||||||
p. 57 |
New Law Effective May 2024 |
The California Department of Public Health has issued a statewide standing order for epinephrine which authorizes a CA school, school district, or county office of education to obtain epinephrine auto-injectors for K-12 schools (ie, elementary, middle, junior high, and high schools). The standing order is acceptable at all pharmacies throughout CA to dispense epinephrine auto-injectors. The maximum number of auto-injectors is four per school per calendar year. If used, these can be refilled (which does not count toward the quantity limit). |
||||||||
Chapter 4: Pharmacy Practice Part 2: Furnishing, Administering and Clinical Services | ||||||||||
p. 69 |
New Law Effective September 2023 |
A pharmacist can furnish oral drugs approved or authorized by the FDA for COVID-19 to a patient that has had a positive test for SARS-CoV-2. When furnishing, the pharmacist must:
|
||||||||
p. 74 |
New Drug Effective July 2023 |
The FDA has approved a new over-the-counter (OTC) naloxone product (brand name RiVive) indicated for the emergency treatment of known or suspected opioid overdose. RiVive will be available as a 3-milligram nasal spray. |
||||||||
p. 75 |
Law update Effective September 2024 |
The “naloxone protocol” has been updated to the “opioid antagonist protocol” for the indication of opioid reversal. Important changes include:
|
||||||||
p. 80-81 |
Law change Effective February 2024 |
The law for furnishing HIV pre-exposure prophylaxis (PrEP) has been updated as follows:
|
||||||||
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||||||||||
p. 132 |
Law change Effective October 2024 |
Restrictions for a take-home supply of methadone for opioid use disorder (OUD) have been simplified and are now permissive of larger quantities. Opioid Treatment Programs are allowed to dispense up to a 28-day supply of methadone for unsupervised self-administration (ie, “take-home”) to qualifying patients for treatment of OUD. Medical practitioners are responsible for determining which patients qualify for a take-home supply based on criteria listed in the regulation (eg, absence of known recent diversion activity, regularity of attendance for supervised methadone administration) in addition to other factors that indicate that the benefits of unsupervised doses outweigh the risks.
|
Chapter 2: Pharmacy Operations | |||||||||
Page p. 7 |
Update Type Law update Effective April 1, 2025 |
||||||||
A new update to the California Code of Regulations (CCR) includes additional requirements for designating a pharmacist-in-charge (PIC):
|
|||||||||
Page p. 8 |
Update Type Law update Effective July 2024 |
||||||||
Continuing education (CE) requirements for pharmacist licensure renewal have been updated. Pharmacists who prescribe schedule II controlled substances must complete at least 1 hour of CE every 4 years pertaining to the risk of addiction associated with these medications. |
|||||||||
Page p. 19 |
Update Type Law change Effective January 2023 |
||||||||
Controlled substance inventory reports must be prepared using an exact physical count, not an estimate, for all federal controlled substance schedules (i.e., schedules II–V) that a pharmacy has in stock (both unopened and opened containers). Prior to this law change, an estimated count was permissible for opened containers of schedule III–V controlled substances based on the number of dosage units. |
|||||||||
Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | |||||||||
Page p. 49-50 |
Update Type Law update |
||||||||
The Notice to Consumers poster has been updated. The poster is now titled “Talk to the Expert” and must replace the “Ask Your Pharmacist!” poster. The content of the poster has been updated to caution consumers to “check” for a list of key information regarding their prescription before leaving the pharmacy. The poster continues to notify consumers of their rights as a patient at the pharmacy. The new poster also includes a QR code that links consumers to other language translations of the poster. If the poster is displayed using a video screen, the QR code must still be capable of being read and displayed for sufficient time for consumers to access the code. |
|||||||||
Page p. 57 |
Update Type New law Effective May 2024 |
||||||||
The California Department of Public Health has issued a statewide standing order for epinephrine which authorizes a CA school, school district, or county office of education to obtain epinephrine auto-injectors for K-12 schools (ie, elementary, middle, junior high, and high schools). The standing order is acceptable at all pharmacies throughout CA to dispense epinephrine auto-injectors. The maximum number of auto-injectors is four per school per calendar year. If used, these can be refilled (which does not count toward the quantity limit). |
|||||||||
Chapter 4: Pharmacy Practice Part 2: Furnishing, Administering and Clinical Services | |||||||||
Page p. 69 |
Update Type New Law Effective September 2023 |
||||||||
A pharmacist can furnish oral drugs approved or authorized by the FDA for COVID-19 to a patient that has had a positive test for SARS-CoV-2. When furnishing, the pharmacist must:
|
|||||||||
Page p. 74 |
Update Type New Drug Effective July 2023 |
||||||||
The FDA has approved a new over-the-counter (OTC) naloxone product (brand name RiVive) indicated for the emergency treatment of known or suspected opioid overdose. RiVive will be available as a 3-milligram nasal spray. | |||||||||
Page p. 75 |
Update Type Law update Effective September 2024 |
||||||||
The “naloxone protocol” has been updated to the “opioid antagonist protocol” for the indication of opioid reversal. Important changes include:
|
|||||||||
Page p. 80-81 |
Update Type Law change Effective February 2024 |
||||||||
The law for furnishing HIV pre-exposure prophylaxis (PrEP) has been updated as follows:
|
|||||||||
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | |||||||||
Page p. 132 |
Update Type Law change Effective October 2024 |
||||||||
Restrictions for a take-home supply of methadone for opioid use disorder (OUD) have been simplified and are now permissive of larger quantities. Opioid Treatment Programs are allowed to dispense up to a 28-day supply of methadone for unsupervised self-administration (ie, “take-home”) to qualifying patients for treatment of OUD. Medical practitioners are responsible for determining which patients qualify for a take-home supply based on criteria listed in the regulation (eg, absence of known recent diversion activity, regularity of attendance for supervised methadone administration) in addition to other factors that indicate that the benefits of unsupervised doses outweigh the risks.
|
CPJE Errata: 8th Edition California Law Summary for CPJE
Corrections or clarifications for the 8th Edition UWorld RxPrep CPJE manual
Page | Description | |
---|---|---|
Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||
p. 32 |
In the Optometrist (OD) row of the table, the right column should read: Must be certified by the Board of Optometry to prescribe drugs. These optometrists will have three letters starting with a T at the end of their license number. Independent authority:
Dependent authority:
|
|
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
p. 135 |
The first sentence of the second paragraph below the “Purchase Requirements for OTC Sales” section should read: Although the DEA requires that the logbook be kept in a secure location for at least two years, California law is more strict and requires records to be kept for at least three years. |
Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||
Page p. 32 |
||
In the Optometrist (OD) row of the table, the right column should read: Must be certified by the Board of Optometry to prescribe drugs. These optometrists will have three letters starting with a T at the end of their license number. Independent authority:
Dependent authority:
|
||
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
p. 135 |
The first sentence of the second paragraph below the “Purchase Requirements for OTC Sales” section should read: Although the DEA requires that the logbook be kept in a secure location for at least two years, California law is more strict and requires records to be kept for at least three years. |